Effectiveness of buprenorphine in double diagnosed patients. Buprenorphine as psychothropic drug

Heroin Addiction and Related Clinical Problems

Volumn 8, Issue 1, 2006, Pages 31-48

  Maremmani, Icro ^a,b,c,e   Pacini, Matteo ^b   Pani, Pier Paolo ^d  

^a UNIVERSITY OF PISA   (Italy)

^b G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

^c AU CNS   (Italy)

^d SerT Cagliari ^*  (Italy)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

Buprenorphine; Treatment of mental disorders

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDOTE; BUPRENORPHINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADDICTION; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DYSPHORIA; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW;

EID: 33646230298     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. A.P.A. (1994): DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. American Psichiatric Association, Washington.
2. BICKEL W. K., STUZER M. L., BEGELOW G. E., LIEBSON I. A., JASINSKI D. R., JOHNSON R. E. (1988): Buprenorphine: dose-related blockade of opioid challenge in opioid dependent humans. J Psychopharmaco Exper Ther (247) 47-53.
3. BODKIN J. A., ZORNBERG G. L., LUKAS S. E., COLE J. O. (1995): Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 15:(1) 49-57.
4. CALLAWAY E. (1996): Buprenorphine for depression: the un-adoptable orphan. Biol Psychiatry. 39:(12) 989-990.
5. CARLSON E. T., SIMPSON M. M. (1963): Opium as a tranquilizer. Am J Psychiatry 120 112-117.
6. DEAN A. J., BELL J., CHRISTIE M. J., MATTICK R. P. (2004): Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry. 19:(8) 510-513.
7. DEROGATIS L. R., LIPMAN R. S., RICKELS K. (1974): The Hopkins Symptom Checklist (HSCL)-A self report symptom inventory. Behav Sci. 19 1-16.
8. EMRICH H. M., VOGT P., HERZ A. (1982): Possible antidepressive effects of opioids: action of buprenorphine. In: VEREBEY K. (Ed.) Opioids in mental illness: theories, clinical observations and treatment possibilities. Ann. N.Y. Acad. Vol. 398. The New York Academy of Sciences, New York, N. Y. pp.
9. EMRICH H. M., VOGT P., HERZ A., KISSLING W. (1982): Antidepressant effects of buprenorphine. Lancet. 25:(2-8300) 709.
10. EXSTEIN I., PICKARD D., AL. E. (1981): Methadone and morphine in depression. Pharmacol Bull. 1729-33.
11. FERRARI A., COCCIA C. P. R., BERTOLINI A., STERNIERI E. (2004): Methadone-metabolism, pharmacokinetics and interactions. Pharmacological research, YPHRS, in press.
12. FINK M., SIMEON J., ITIL T. M., FREEDMAN A. M. (1970): Clinical antidepressant activity of cyclazocine-a narcotic antagonist. Clin Pharmacol Ther:(11) 41-48.
13. FRECSKA E., PERENYI A., ARATO M. (2003): Blunted prolactin response to fentanyl in depression. Normalizing effect of partial sleep deprivation. Psychiatry Res. 118:(2) 155-164.
14. GASQUET I., LANCON C., PARQUET P. (1999): Predictive factors for patient maintenance on buprenorphine high dosage treatment: a naturalistic study in primary care. Encephale. 25:(6) 645-651.
15. GERRA G. (2002): Buprenorfina in associazione a trattamento prolungato con naltrexone in soggetti affetti da grave dipendenza da eroina. In: A L. (Ed.) L'uso della buprenorfina nel trattamento della tossicodipendenza. FrancoAngeli, Milano. pp.
16. GERRA G., BORELLA F., ZAIMOVIC A., MOI G., BUSSANDRI M., BUBICI C., BERTACCA S. (2004): Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 75:(1) 37-45.
17. HEIKKILA L., RIMON R., TERENIUS L. (1990): Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res. 34:(3) 229-236.
18. HOLTZMAN S. G. (1982): Phencyclidine-like discriminative stimulus properties of psychotomimetic opioids. Ann NY Acad Sci:(398) 230-239.
19. JAFFEE J. H., MARTIN W. R. (1990): Opioid analgesics and antagonists. In: IN GILMAN A. G., RALL W. R., NIES A. S., TAYLOR P. (Eds.): Goodman and Gilmans: the pharmacological basis of therapeutics. 8th ed. Pergamon Press, New York. pp. 488-521.
20. JAGADHEESAN K., MUIRHEAD D. (2004): Possible manic potential of buprenorphine. Aust N Z J Psychiatry. 38:(7) 560-561.
21. JOHNSON R., JAFFE J., FUDALA P. (1992): A controlled comparative trial of buprenorphine and methadone treatment for opioid dependence. JAMA. 267 2750-2755.
22. JUDD L. L., PARKER D. C., JANOWSKY D. S., SEGAL D. S., RISCH S. C., HUEY L. Y. (1982): The effect of methadone on the behavioral and neuroendocrine responses of manic patients. Psychiatry Research. 7:(2) 163-170.
23. KOSTEN T. R., MORGAN C., KOSTEN T. A. (1990): Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 7:(1) 51-54.
24. KRAEPELIN E. (1921): Manic-Depressive Illness and Paranoia. Livingstone, Edinburgh.
25. LAQUEILLE X., POIRIER M. F., JALFRE V., BOURDEL M. C., WILLARD D., OLIE J. P. (2001): Predictive factors of response to buprenorphine in the substitutive treatment of heroin addicts. Results of a multicenter study of 73 patients. Presse Med. 30:(32) 1581-1585.
26. LEHMANN H. E., J.V. A., A. G., T.A. B. (1971): Treatment of depression with dexedrine and demerol. Cur Ther Res:(13) 42-49.
27. LEVINSON I., ROSENTHAL R. N. (1995): Methadone withdrawal psychosis. J Clin Psychiatry. 56:(2) 73-76.
28. LING W., WESSON D. R., CHARUVASTRA C., KLETT C. J. (1996): A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 53:(5) 401-407.
29. MAREMMANI I., BALESTRI C., SBRANA A., TAGLIAMONTE A. (2003): Substance (ab)use during methadone and naltrexone treatment. Interest of adequate methadone dosage. Journal of Maintenance in the Addictions. 2:(1-2) 19-36.
30. MAREMMANI I., CANONIERO S., PACINI M. (2002): Psico(pato)logia dell'addiction'. Un'ipotesi interpretativa. Ann Ist Super Sanità. 38:(3) 241-257.
31. MAREMMANI I., CANONIERO S., PACINI M., LOVRECIC M., TAGLIAMONTE A. (2001): An eigh year longitudinal study of psychiatric patients on methadone maintenance treatment. Odvisnosti. 2:(1-2) 22-24.
32. MAREMMANI I., DAINI L. (2000): Sintomi di Comorbidità Psichiatrica durante il trattamento della dipendenza da eroina. Bollettino per le Farmacodipendenze e l'Alcolismo. 23:(1) 29-38.
33. MAREMMANI I., MARINI G., FORNAI F. (1998): Naltrexone induced Panic Attacks. Am J Psychiatry. 155:(3) 447.
34. MAREMMANI I., PACINI M., GIUNTOLI G., LOVRECIC M., PERUGI G. (2004): Naltrexone as maintenance therapy for heroin addiction: Predictors of response. Heroin Add & Rel Clin Probl. 6:(1) 43-52.
35. MAREMMANI I., PACINI M., LOVRECIC M., LUBRANO S., PERUGI G. (2003): Maintenance Therapy with opioid agonist for heroin addicted patients. Usefulness in the treatment of comorbid psychiatric diseases. In: WAAL H., HAGA E. (Eds.): Maintenance Treatment of Heroin Addiction. Evidence at the Crossroads. Cappelen Akademisk Forlag, Oslo. pp. 221-233.
36. MAREMMANI I., ZOLESI O., AGUECI T., CASTROGIOVANNI P. (1993): Methadone Doses and Psychopathological Symptoms during Methadone Maintenance. J Psychoactive Drugs. 25(3) 253-263.
37. MAREMMANI I., ZOLESI O., DAINI L., CASTROGIOVANNI P., TAGLIAMONTE A. (1995): Fluoxetine improves outcome in Addicted Patients Treated With Opioid Antagonists. Am J Addict. 4:(3) 267-271.
38. MARTIN W. R. (1979): History and development of mixed opioid agonists, partial agonists and antagonists. Br J Clin Pharmacol. J Suppl 3 273S-279S.
39. MATUSSEK N., HOEHE M. (1989): Neuropsychobiology. Investigations with the specific mu-opiate receptor agonist fentanyl in depressive patients: growth hormone, prolactin, cortisol, noradrenaline and euphoric responses. J Neuropsychiatry Clin Neurosci. 1:(3) 291-295.
40. MAYER-GROSS W., SLATER E., ROTH M. (1956): Clinical Psychiatry. Williams & Wilkins, Baltimore.
41. MENDELSON J. H., TEOH S. K., MELLO N. K., ELLINGBOE J. (1992): Buprenorphine attenuates the effects of cocaine on adrenocorticotropin (ACTH) secretion and mood states in man. Neuropsychopharmacology. 7:(2) 157-162.
42. MORGAN L., CALLOWAY E. (1990): Buprenorphine responders. Biol Psychiatry:(28) 1078-1080.
43. NABER D., JUNGKUNZ G. (1986): Opiate receptor sensitivity in depressed patients before and after clomipramine treatment. J Affect Disord. 11:(1) 59-62.
44. NUTT D. J. (1997): Receptor pharmacology of buprenorphine. Research and Clinical Forums. 19:(2) 9-15.
45. PACINI M., MAREMMANI I. (2005): Medical meaning of psychosocial issues of heroin addiction. Heroin Add & Rel Clin Probl. 7:(2) 37-48.
46. PANI P. P., MAREMMANI I., PIRASTU R., TAGLIAMONTE A., GESSA G. L. (2000): Buprenorphine: A Controlled Clinical Trial on the Efficacy in the Treatment of Opioid Dependence. Drug Alcohol Depend. 60 39-50.
47. PENDE A., MUSSO N. R., MONTALDI M. L., PASTORINO G., ARZESE M., DEVILLA L. (1986): Evaluation of the effects induced by four opiate drugs, with different affinities to opioid receptor subtypes, on anterior pituitary LH, TSH, PRL and GH secretion. Biomedicine and Pharmacotherapy. 40:(5) 178-183.
48. PHAN O., SANCHEZ M., BOUTHILLON-HEITZMANN P. (2005): Absence of correlation between mental disorders and high-dose buprenorphine. A case-control study. Presse Med. 34:(10) 711-718.
49. POIRIER M. F., LAQUEILLE X., JALFRE V., WILLARD D., BOURDEL M. C., FERMANIAN J., OLIE J. P. (2004): Clinical profile of responders to buprenorphine as a substitution treatment in heroin addicts: results of a multicenter study of 73 patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 28:(2) 267-272.
50. RESNICK R. B., FALK F. (1987): Buprenorphine: pilot trials in borderline patients and opiate dependence: treatment of a common disorder? In: HARRIS L. S. (Ed.) NIDA Research Monograph: Problems of drug dependence. US Governement Printing Office, Washington DC. pp.
51. ROBERTSON A. G., JACKMAN H., MELTZER H. Y. (1984): Prolactin response to morphine in depression. Psychiatry Res. 11:(4) 353-364.
52. ROTHMAN R. B., GORELICK D. A., HEISHMAN S. J., EICHMILLER P. R., HILL B. H., NORBECK J., LIBERTO J. G. (2000): An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J Subst Abuse Treat. 18:(3) 277-281.
53. SCHMAUSS C., YASSOURIDIS A., EMRICH H. M. (1987): Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry. 144:(10) 1340-1342.
54. SCHOTTENFELD R. S., PAKES J. R., KOSTEN T. R. (1998): Prognostic factors in buprenorphine- versus methadone-maintained patients. J Nerv Ment Dis. 186:(1) 35-43.
55. SCHURKS M., OVERLACK M., BONNET U. (2005): Naltrexone treatment of combined alcohol and opioid dependence: deterioration of co-morbid major depression. Pharmacopsychiatry. 38:(2) 100-102.
56. SEIFERT J., METZNER C., PAETZOLD W., BORSUTZKY M., OHLMEIER M., PASSIE T., HAUSER U., BECKER H., WIESE B., EMRICH H. M., SCHNEIDER U. (2005): Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Add Biol:(2) 157-164.
57. SHREERAM S. S., MCDONALD T., DENNISON S. (2001): Psychosis after ultrarapid opiate detoxification. Am J Psychiatry. 158:(6) 970.
58. STITZER M., SCHUH K., WALSH S., PRESTON K., BIGELOW G. (1994): The effects of buprenorphine in morphine-maintained subject. In: HARRIS L. (Ed.) Problems of drug dependence 1993. NIDA Research Monograph Series. NIDA, Baltimore, pp. 383.
59. STITZER M., WALSH S., PRESTON K., CONE E., BIGELOW G. (1994): Clinical pharmacology of buprenorphine: ceiling effects at high doses Clinical Pharmacology and Therapeutics. 55 569-580.
60. STRAIN E. C., STITZER M. L., LIEBSON I. A., BIGELOW G. E. (1996): Buprenorphine versus methadone in the treatment of Opioid Dependence: Self-reports, urinalysis and Addiction Severity index. J Clin Psychopharmacol. 16:(1) 58-67.
61. TORRENS M., SAN L., CAMI J. (1993): Buprenorphine versus heroin dependence: comparison of toxicologic and psychopathologic characteristics. Am J Psychiatry. 150:(5) 822-824.
62. VARGA E., SUGERMAN A. A., APTER J. (1982): The effect of codeine on involutional and senile depression. In: VEREBEY K. (Ed.) Opioids in mental illness: theories, clinical observations and treatment possibilities. Ann. N. Y. Acad. V. 398. The New York Academy of Sciences, New York, N. Y. pp.
63. WALBY F. A., BORG P., EIKESETH P. H., NEEGAARD E., KJERPESETH K., BRUVIK S., WAAL H. (2000): Use of methadone in the treatment of psychotic patients with heroin dependence. Tidsskrift for Den Norske Laegeforening. 120:(2) 195-198.
64. WALSH S. L., PRESTON K. L., STITZER M. L., CONE E. J., BIGELOW G. E. (1994): Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 55:(5) 569-580.
65. WEIZMAN A., GIL-AD I., GRUPPER D., TYANO S., LARON Z. (1987): The effect of acute and repeated electroconvulsive treatment on plasma beta-endorphin, growth hormone, prolactin and cortisol secretion in depressed patients. Psychopharmacology (Berl). 93:(1) 122-126.
66. ZHANG A. Z., ZHOU G. Z., XI G. F., GU N. F., XIA Z. Y., YAO J. L., CHANG J. K., WEBBER R., POTKIN S. (1985): Lower CSF level of dynorhin(1-8) immunoreactivity in schizophrenic patients. Neuropeptides. 5:(4-6) 553-556.